GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. GRI Bio Inc market cap is $2.45M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. GRI Bio Inc 52 week high is $64.12 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. GRI Bio Inc 52 week low is $1.09 as of November 22, 2026.
GRI Bio Inc stock price today is $1.12.
GRI Bio Inc stock price yesterday was $1.12.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. GRI Bio Inc's P/E ratio is -0.13.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. GRI Bio Inc P/B ratio is 0.278.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. GRI Bio Inc 50-day moving average is $1.68.